First, if the patients with acute-on-chronic liver failure related to hepatitis B had galectin-3 methylated promoter, they would have shorter survival time, higher 3-month mortality, and higher model for end-stage liver disease (MELD) score (59). This evidence concerns the gene LGALS3 and End Stage Liver Disease.